SEI Investments’s Ascendis Pharma A/S ASND Stock Holding History

SEI Investments’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$49.4M	Sell	216,981 -20,888	-9%	-$5.29M	0.04%	422
2026 Q2	$63.4M	Sell	237,869 -113,277	-32%	-$26.5M	0.06%	374
2026 Q1	$80.3M	Buy	351,146 +69,673	+25%	+$15.6M	0.07%	287
2025 Q4	$60M	Buy	281,473 +76,154	+37%	+$15.7M	0.06%	341
2025 Q3	$40.8M	Sell	205,319 -31,251	-13%	-$5.83M	0.04%	441
2025 Q2	$40.8M	Sell	236,570 -21,443	-8%	-$3.49M	0.05%	412
2025 Q1	$40.2M	Sell	258,013 -5,569	-2%	-$796K	0.05%	388
2024 Q4	$36.3M	Sell	263,582 -10,165	-4%	-$1.34M	0.05%	423
2024 Q3	$40.9M	Buy	273,747 +9,176	+3%	+$1.24M	0.05%	381
2024 Q2	$36.1M	Sell	264,571 -81,615	-24%	-$11.1M	0.05%	382
2024 Q1	$52.3M	Sell	346,186 -15,644	-4%	-$2.23M	0.08%	279
2023 Q4	$45.6M	Sell	361,830 -34,610	-9%	-$3.45M	0.07%	297
2023 Q3	$37.1M	Sell	396,440 -13,944	-3%	-$1.3M	0.07%	310
2023 Q2	$36.6M	Sell	410,384 -65,637	-14%	-$5.71M	0.06%	324
2023 Q1	$51M	Buy	476,021 +38,770	+9%	+$4.44M	0.09%	222
2022 Q4	$53.4M	Sell	437,251 -36,268	-8%	-$4.21M	0.12%	176
2022 Q3	$48.9M	Buy	473,519 +21,718	+5%	+$2.06M	0.11%	190
2022 Q2	$42M	Buy	451,801 +7,242	+2%	+$683K	0.09%	233
2022 Q1	$52.2M	Buy	444,559 +21,868	+5%	+$2.53M	0.1%	192
2021 Q4	$56.9M	Buy	422,691 +33,468	+9%	+$4.98M	0.11%	198
2021 Q3	$62M	Buy	389,223 +90,902	+30%	+$12.4M	0.13%	161
2021 Q2	$39.2M	Buy	298,321 +35,929	+14%	+$4.79M	0.09%	231
2021 Q1	$33.8M	Buy	262,392 +19,290	+8%	+$2.93M	0.09%	232
2020 Q4	$40.6M	Buy	243,102 +8,328	+4%	+$1.38M	0.1%	186
2020 Q3	$36.2M	Buy	234,774 +84,122	+56%	+$12.1M	0.1%	172
2020 Q2	$22.3M	Buy	150,652 +64,466	+75%	+$8.85M	0.07%	279
2020 Q1	$9.7M	Buy	86,186 +20,278	+31%	+$2.63M	0.04%	483
2019 Q4	$9.17M	Buy	65,908 +899	+1%	+$100K	0.03%	619
2019 Q3	$6.26M	Buy	65,009 +20,938	+48%	+$2.34M	0.02%	828
2019 Q2	$5.08M	Buy	44,071 +18,971	+76%	+$2.27M	0.02%	924
2019 Q1	$2.95M	Buy	+25,100	New	+$2.2M	0.01%	1150

Other funds holding ASND

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ARS Investment Partners New York $2.23B AUM 74.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

USS Investment Management London, United Kingdom $25.1B AUM 30.53% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SEI Investments's ASND Position: Q3 2026 in Review

SEI Investments reduced its Ascendis Pharma A/S (ASND) stake by 8.8% in Q3 2026, selling an estimated $5.29M and leaving 216,981 shares worth $49.4M. The position accounts for 0.04% of the portfolio, ranked #422.

SEI Investments first reported a position in ASND in Q1 2019 and has held it in 31 quarters since. The position peaked at $80.3M in Q1 2026. 156 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

SEI Investments held 216,981 shares of Ascendis Pharma A/S worth $49.4M as of Q3 2026.
SEI Investments sold 20,888 Ascendis Pharma A/S shares in Q3 2026, an estimated $5.29M.
Ascendis Pharma A/S made up 0.04% of SEI Investments's portfolio in Q3 2026, its #422 holding.
SEI Investments first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 31 quarters since.
SEI Investments's Ascendis Pharma A/S position peaked at $80.3M in Q1 2026.
156 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.